Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies
Autor: | Jitka A. I. Virag, Julie L. Horton |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
medicine.medical_specialty ephrinA1 Cardiotonic Agents Recombinant Fusion Proteins medicine.medical_treatment Myocardial Infarction Ischemia Review ischemia Disease 030204 cardiovascular system & hematology Ligands Catalysis lcsh:Chemistry Translational Research Biomedical Inorganic Chemistry 03 medical and health sciences 0302 clinical medicine medicine Animals Humans Myocardial infarction Physical and Theoretical Chemistry Intensive care medicine lcsh:QH301-705.5 therapeutic strategies Molecular Biology Spectroscopy Reduction (orthopedic surgery) Cardioprotection Myocardial tissue business.industry Organic Chemistry Disease Management Ephrin-A1 General Medicine medicine.disease Combined Modality Therapy reperfusion Immunoglobulin Fc Fragments Computer Science Applications Functional integrity Treatment Outcome 030104 developmental biology lcsh:Biology (General) lcsh:QD1-999 cardioprotection business |
Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 20, Iss 6, p 1449 (2019) |
ISSN: | 1422-0067 |
Popis: | Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |